More rebates in Italy threaten profitability of pure biotech firms like Amgen and Celgene
This article was originally published in Scrip
Pure biotech companies operating in Italy will have trouble staying profitable if next year they have to stump up some €800 million in the form of rebates, Riccardo Palmisano, senior vice- president of Italy's biotech association, Assobiotec, told Scrip. The biotech companies operating in Italy, which include Amgen, Genzyme and Celgene, are particularly exposed to potential clawback because their products are almost exclusively sold to hospitals, the drugs budget for which is being strictly capped.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.